Publications

Google Scholar profile | Download BibTeX file

2022 | 2021 | 2020 | 2018 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 | 1982 | 1980

2022

  • Anderson, K. M., Guo, Z., Zhao, J., & Sun, L. Z. (2022). A unified framework for weighted parametric group sequential design. Biometrical Journal. https://doi.org/10.1002/bimj.202100085

  • Miao, G., Liao, J. J., Yang, J., & Anderson, K. (2022). A gated group sequential design for seamless phase II/III trial with subpopulation selection. arXiv Preprint arXiv:2206.12536. https://doi.org/10.48550/arXiv.2206.12536

  • Mukhopadhyay, P., Ye, J., Anderson, K. M., Roychoudhury, S., Rubin, E. H., Halabi, S., & Chappell, R. J. (2022). Log-rank test vs MaxCombo and difference in restricted mean survival time tests for comparing survival under nonproportional hazards in immuno-oncology trials: A systematic review and meta-analysis. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2022.2666

  • Zhao, Y., Xiao, N., Anderson, K., & Zhang, Y. (2022). Electronic common technical document submission with analysis using R. Clinical Trials. https://doi.org/10.1177/17407745221123244

2021

  • Bautista, O., & Anderson, K. (2021). Sample size estimation and power analysis: Time to event data. In Handbook of statistical methods for randomized controlled trials (pp. 275–300). Chapman; Hall/CRC. https://doi.org/10.1201/9781315119694

  • Chen, T.-Y., Zhao, J., Sun, L., & Anderson, K. M. (2021). Multiplicity for a group sequential trial with biomarker subpopulations. Contemporary Clinical Trials, 101, 106249. https://doi.org/10.1016/j.cct.2020.106249

  • Roychoudhury, S., Anderson, K. M., Ye, J., & Mukhopadhyay, P. (2021). Robust design and analysis of clinical trials with nonproportional hazards: A straw man guidance from a cross-pharma working group. Statistics in Biopharmaceutical Research, 1–15. https://doi.org/10.1080/19466315.2021.1874507

2020

  • León, L. F., Lin, R., & Anderson, K. M. (2020). On weighted log-rank combination tests and companion Cox model estimators. Statistics in Biosciences, 12(2), 225–245. https://doi.org/10.1007/s12561-020-09276-1

  • Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020). Alternative analysis methods for time to event endpoints under nonproportional hazards: A comparative analysis. Statistics in Biopharmaceutical Research, 12(2), 187–198. https://doi.org/10.1080/19466315.2019.1697738

  • Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020). Rejoinder to letter to the editor “the hazards of period specific and weighted hazard ratios”. Statistics in Biopharmaceutical Research, 12(4), 520. https://doi.org/10.1080/19466315.2020.1825522

  • Tian, L., Jin, H., Uno, H., Lu, Y., Huang, B., Anderson, K. M., & Wei, L. (2020). On the empirical choice of the time window for restricted mean survival time. Biometrics, 76(4), 1157–1166. https://doi.org/10.1111/biom.13237

  • Wang, S., Ye, S., Anderson, K. M., & Zhang, Y. (2020). r2rtf—an R package to produce Rich Text Format (RTF) tables and figures. PharmaSUG. https://www.pharmasug.org/proceedings/2020/DV/PharmaSUG-2020-DV-198.pdf

2018

  • Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): A randomised, placebo-controlled trial. The Lancet, 392(10161), 2269–2279. https://doi.org/10.1016/S0140-6736(18)32328-6

  • Chen, C., Anderson, K., Mehrotra, D. V., Rubin, E. H., & Tse, A. (2018). A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development. Contemporary Clinical Trials, 64, 238–242. https://doi.org/10.1016/j.cct.2017.09.006

  • Chen, C., Anderson, K., Mehrotra, D. V., Rubin, E. H., & Tse, A. (2018). Designing clinical trials in tumor indications with a positive signal in phase 1. Cancer Research, 78(13_Supplement), 4759–4759. https://doi.org/10.1158/1538-7445.AM2018-4759

  • Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., et al. (2018). Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with Pembrolizumab. Clinical Cancer Research, 24(20), 4960–4967. https://doi.org/10.1158/1078-0432.CCR-17-2386

  • Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., et al. (2018). Correction: Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with Pembrolizumab. Clinical Cancer Research, 24(23), 6098–6098. https://doi.org/10.1158/1078-0432.CCR-18-3340

  • Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G., Garon, E. B., Riess, J. W., Jain, L., Mayawala, K., Kang, J., Ebbinghaus, S. W., et al. (2018). Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clinical Cancer Research, 24(23), 5841–5849. https://doi.org/10.1158/1078-0432.CCR-18-0415

2016

  • Blank, C., Ma, J., Grob, J., Larkin, J., Neyns, B., McNeil, C., Lotem, M., Richtig, E., Masucci, G., Petrella, T., Ribas, A., Wang, J., Ibrahim, N., Anderson, K., & Arance, A. (2016). Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006. Annals of Oncology, 27, vi382. https://doi.org/10.1093/annonc/mdw379.10

2015

2014

  • Anderson, K. M. (2014). Group sequential design in R. In Clinical trial biostatistics and biopharmaceutical applications (pp. 179–209). CRC Press New York. https://doi.org/10.1201/b17716

  • Anderson, K. M. (2014). Timing and frequency of interim analyses in confirmatory trials. In Practical considerations for adaptive trial design and implementation (pp. 115–123). Springer. https://doi.org/10.1007/978-1-4939-1100-4_6

  • Anderson, K., Joffe, M., & Kosorok, M. R. (2014). University of Pennsylvania 6th annual conference on statistical issues in clinical trials: Dynamic treatment regimes (morning session). Clinical Trials, 11(4), 418–425. https://doi.org/10.1177/1740774514538553

  • He, W., Pinheiro, J., & Kuznetsova, O. M. (2014). Practical considerations for adaptive trial design and implementation. Springer. https://doi.org/10.1007/978-1-4939-1100-4

  • Herzog, T., Anderson, K., Wang, J., & Xu, R. (2014). Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor-positive target. Gynecologic Oncology, 133, 178–179. https://doi.org/10.1016/j.ygyno.2014.03.470

  • Joseph, R. W., Elassaiss-Schaap, J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Hwu, W.-J., Kefford, R., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P., Perrone, A. M., Kang, S. P., Ebbinghaus, S., Anderson, K. M., & Gangadhar, T. C. (2014). Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. Journal of Clinical Oncology, 32(15_suppl), 3015–3015. https://doi.org/10.1200/jco.2014.32.15_suppl.3015

  • Naumann, R., Bidzinski, M., Lovejoy, C., Anderson, K., Rangwala, R., & Kutarska, E. (2014). CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial. Gynecologic Oncology, 133, 177–178. https://doi.org/10.1016/j.ygyno.2014.03.468

  • Zhou, J., Adewale, A., Shentu, Y., Liu, J., & Anderson, K. (2014). Information-based sample size re-estimation in group sequential design for longitudinal trials. Statistics in Medicine, 33(22), 3801–3814. https://doi.org/10.1002/sim.6192

2012

  • Anderson, K. M., Chan, I. S., & Li, X. (2012). An adaptive design for case-driven vaccine efficacy study when incidence rate is unknown. Statistics and Its Interface, 5(4), 391–399. https://doi.org/10.4310/SII.2012.v5.n4.a2

  • He, W., Kuznetsova, O. M., Harmer, M., Leahy, C., Anderson, K., Dossin, N., Li, L., Bolognese, J., Tymofyeyev, Y., & Schindler, J. (2012). Practical considerations and strategies for executing adaptive clinical trials. Drug Information Journal: DIJ/Drug Information Association, 46(2), 160–174. https://doi.org/10.1177/0092861512436580

  • Liu, Q., Li, G., Anderson, K. M., & Lim, P. (2012). On efficient two-stage adaptive designs for clinical trials with sample size adjustment. Journal of Biopharmaceutical Statistics, 22(4), 617–640. https://doi.org/10.1080/10543406.2012.678226

2011

  • Rubin, E. H., Anderson, K. M., & Gause, C. K. (2011). The BATTLE trial: A bold step toward improving the efficiency of biomarker-based drug development. Cancer Discovery, 1(1), 17–20. https://doi.org/10.1158/2159-8274.CD-11-0036

2010

  • Anderson, K. M., & Clark, J. B. (2010). Fitting spending functions. Statistics in Medicine, 29(3), 321–327. https://doi.org/10.1002/sim.3737

  • Anderson, K. M., & Clark, J. (2010). Group sequential design: Selecting appropriate bounds. Journal of Clinical Oncology, 28(15_suppl), e13159–e13159. https://doi.org/10.1200/jco.2010.28.15\_suppl.e13159

  • Chen, Y. J., & Anderson, K. M. (2010). A “MiniPool” approach for combined phase IIB/III trial in patients with life-threatening disease: An application of the closed testing principle. Statistics in Biopharmaceutical Research, 2(1), 62–71. https://doi.org/10.1198/sbr.2009.0038

  • Ellenberg, S., Ruberg, S., Simon, R., Wang, S.-J., Xu, L.-A., & Anderson, K. (2010). Closing discussion. Clinical Trials, 7(5), 611–616. https://doi.org/10.1177/1740774510380503

  • Gallo, P., Anderson, K., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2010). Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. Journal of Biopharmaceutical Statistics, 20(6), 1115–1124. https://doi.org/10.1080/10543406.2010.514452

  • Rubin, E. H., & Anderson, K. M. (2010). Finding the right dose for cancer therapeutics—can we do better? Clinical Cancer Research, 16(4), 1085–1087. https://doi.org/10.1158/1078-0432.CCR-09-3246

2009

  • Gaydos, B., Anderson, K. M., Berry, D., Burnham, N., Chuang-Stein, C., Dudinak, J., Fardipour, P., Gallo, P., Givens, S., Lewis, R., et al. (2009). Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal, 43(5), 539–556. https://doi.org/10.1177/009286150904300503

  • Lupinacci, L., Anderson, K., Sun, L., & Tymofyeyev, Y. (2009). Novel phase i design for oncology research. Journal of Clinical Oncology, 27(15_suppl), 2517–2517. https://doi.org/10.1200/jco.2009.27.15\_suppl.2517

2008

2007

  • Anderson, K. M. (2007). Optimal spending functions for asymmetric group sequential designs. Biometrical Journal: Journal of Mathematical Methods in Biosciences, 49(3), 337–345. https://doi.org/10.1002/bimj.200510205

  • Cohen, Y. C., Liu, K. S., Heyden, N. L., Carides, A. D., Anderson, K. M., Daifotis, A. G., & Gann, P. H. (2007). Detection bias due to the effect of finasteride on prostate volume: A modeling approach for analysis of the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 99(18), 1366–1374. https://doi.org/10.1093/jnci/djm130

2006

  • Chuang-Stein, C., Anderson, K., Gallo, P., & Collins, S. (2006). Sample size reestimation: A review and recommendations. Drug Information Journal: DIJ/Drug Information Association, 40(4), 475–484. https://doi.org/10.1177/216847900604000413

  • Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2006). Adaptive designs in clinical drug development—an executive summary of the PhRMA working group. Journal of Biopharmaceutical Statistics, 16(3), 275–283. https://doi.org/10.1080/10543400600614742

2004

  • Liu, Q., Anderson, K. M., & Pledger, G. W. (2004). Benefit-risk evaluation of multi-stage adaptive designs. Sequential Analysis, 23(3), 317–331. https://doi.org/10.1081/SQA-200027049

2003

  • Berry, S., Berry, D., Mackey, H., Cooper, J., Anderson, K., & Barnathan, E. (2003). Does use of a bayesian approach help to confirm or reject the reported mortality benefit of abciximab in percutaneous coronary intervention? Results from 8 randomized controlled trials. Circulation, 108, 767–768.

2002

  • Antman, E. M., Cooper, H., Gibson, C., Lemos, J. A. de, McCabe, C., Giugliano, R., Coussement, P., Murphy, S., Scherer, J., Anderson, K., et al. (2002). Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction. Insights from TIMI 14 and InTIME-II. European Heart Journal, 23(12), 928–933. https://doi.org/10.1053/euhj.2001.2964

  • Kereiakes, D. J., Lincoff, A. M., Anderson, K. M., Achenbach, R., Patel, K., Barnathan, E., Califf, R. M., & Topol, E. J. (2002). Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. American Journal of Cardiology, 90(6), 628–630. https://doi.org/10.1016/s0002-9149(02)02568-7

2001

  • Akkerhuis, K. M., Deckers, J. W., Lincoff, A. M., Tcheng, J. E., Boersma, E., Anderson, K., Balog, C., Califf, R. M., Topol, E. J., & Simoons, M. L. (2001). Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA, 286(1), 78–82. https://doi.org/10.1001/jama.286.1.78

  • Anderson, K. M., Califf, R. M., Stone, G. W., Neumann, F.-J., Montalescot, G., Miller, D. P., Ferguson, J. J., Willerson, J. T., Weisman, H. F., & Topol, E. J. (2001). Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. Journal of the American College of Cardiology, 37(8), 2059–2065. https://doi.org/10.1016/s0735-1097(01)01290-6

  • Kereiakes, D., Anderson, K., Achenbach, R., Melsheimer, R., Kurz, M., & Barnathan, E. (2001). Abciximab survival advantage is not explained by reduction in early major cardiac events: EPIC, EPILOG and EPISTENT 3 year analysis. Circulation, 104, 87–88.

2000

  • Antman, E. M., Gibson, C., Lemos, J. A. de, Giugliano, R., McCabe, C., Coussement, P., Menown, I., Nienaber, C., Rehders, T., Frey, M., et al. (2000). Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI 14. European Heart Journal, 21(23), 1944–1953. https://doi.org/10.1053/euhj.2000.2243

  • Lemos, J. A. de, Antman, E. M., Gibson, C. M., McCabe, C. H., Giugliano, R. P., Murphy, S. A., Coulter, S. A., Anderson, K., Scherer, J., Frey, M. J., et al. (2000). Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial. Circulation, 101(3), 239–243. https://doi.org/10.1161/01.cir.101.3.239

  • The Abciximab in Ischemic Stroke Investigators. (2000). Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke, 31(3), 601–609. https://doi.org/10.1161/01.str.31.3.601

  • Kereiakes, D. J., Berkowitz, S. D., Lincoff, A. M., Tcheng, J. E., Wolski, K., Achenbach, R., Melsheimer, R., Anderson, K., Califf, R. M., & Topol, E. J. (2000). Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. American Heart Journal, 140(1), 74–80. https://doi.org/10.1067/mhj.2000.106615

  • Kereiakes, D., Lincoff, A., Achenbach, R., Melsheimer, R., Kurz, M., Califf, R., Anderson, K., & Topol, E. (2000). Long-term abciximab survival advantage is not explained by reduction in early major cardiac events. American Journal of Cardiology, 86, 13I–13I.

  • Lincoff, A. M., Mark, D. B., Tcheng, J. E., Califf, R. M., Bala, M. V., Anderson, K. M., Davidson-Ray, L., Knight, J. D., Cabot, C. F., & Topol, E. J. (2000). Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: Results from the EPILOG randomized trial. Circulation, 102(24), 2923–2929. https://doi.org/10.1161/01.cir.102.24.2923

1999

  • Anderson, K., Cabot, C., & Tcheng, J. (1999). Abciximab reduces in-hospital events among patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 84, 67P–67P.

  • Anderson, K. M., Bala, M. V., & Weisman, H. F. (1999). An industry perspective on health economics studies. The American Heart Journal, 137(5), S129–S132.

  • Antman, E. M., Giugliano, R. P., Gibson, C. M., McCabe, C. H., Coussement, P., Kleiman, N. S., Vahanian, A., Adgey, A. J., Menown, I., Rupprecht, H.-J., et al. (1999). Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation, 99(21), 2720–2732. https://doi.org/10.1161/01.cir.99.21.2720

  • Cabot, C., Anderson, K., Tcheng, J., & Lincoff, A. (1999). Abciximab reduces procedure time among patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 84, 71P–71P.

  • Coussement, P., Antman, E., Giugliano, R., McCabe, C., Schuhwerk, K., Gibson, C., Scherer, J., Anderson, K., Braunwald, E., & Van de Werf, F. (1999). Comparison of two different thrombolytic regimens with and without abciximab in ST-elevation myocardial infarction: Observations from the TIMI 14 trial. Circulation, 100, 650–650.

  • Lincoff, A. M., Tcheng, J. E., Califf, R. M., Kereiakes, D. J., Kelly, T. A., Timmis, G. C., Kleiman, N. S., Booth, J. E., Balog, C., Cabot, C. F., et al. (1999). Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial. Circulation, 99(15), 1951–1958. https://doi.org/10.1161/01.cir.99.15.1951

  • Mauskopf, J., Bala, M., Hermiller, J., Barber, B., & Anderson, K. (1999). TPCT2: Cost-effectiveness of abciximab in percutaneous coronary intervention patients: Results from a meta-analysis. Value in Health, 3(2), 153. https://doi.org/10.1016/S1098-3015(11)70886-5

  • Topol, E. J., Mark, D. B., Lincoff, A. M., Cohen, E., Burton, J., Kleiman, N., Talley, D., Sapp, S., Booth, J., Cabot, C. F., et al. (1999). Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. The Lancet, 354(9195), 2019–2024. https://doi.org/10.1016/s0140-6736(99)10018-7

1998

  • Antman, E., Giugliano, R., McCabe, C., Gibson, C., Adgey, A., Ghali, M., Coussement, P., Anderson, K., Scherer, J., Van de Werf, F., et al. (1998). Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of TIMI 14 trial. Journal of the American College of Cardiology, 31(2SA), 191A–191A.

  • Gibson, C., Giugliano, R., Anderson, K., Scherer, J., McCabe, C., & Antman, E. (1998). Abciximab enhances thrombolysis: A comparison of abciximab alone versus abciximab plus low dose thrombolytics using the corrected TIMI frame count. Circulation, 98, 559–560.

  • Kereiakes, D., Lincoff, A., Simoons, M., deBoer, M., Tcheng, J., Vahanian, A., Anderson, K., Cabot, C., & Califf, R. (1998). Abciximab benefit in coronary intervention has no gender bias: Results of EPIC, EPILOG and CAPTURE trials. American Journal of Cardiology, 82, 95S–95S.

  • Kereiakes, D. J., Lincoff, A. M., Miller, D. P., Tcheng, J. E., Cabot, C. F., Anderson, K. M., Weisman, H. F., Califf, R. M., & Topol, E. J. (1998). Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications. Circulation, 97(9), 857–864. https://doi.org/10.1161/01.cir.97.9.857

  • Kereiakes, D., Berkowitz, S., Anderson, K., Simoons, M., Vahanian, A., Lincoff, A., Tcheng, J., Weisman, H., Califf, R., & Topol, E. (1998). Abciximab associated thrombocytopenia: Evidence for a complex interaction with heparin. Journal of the American College of Cardiology, 31, 55–55.

  • Kleiman, N. S., Lincoff, A. M., Kereiakes, D. J., Miller, D. P., Aguirre, F. V., Anderson, K. M., Weisman, H. F., Califf, R. M., & Topol, E. J. (1998). Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial. Circulation, 97(19), 1912–1920. https://doi.org/10.1161/01.cir.97.19.1912

  • Koreiakos, D., Lincoff, A., Simoons, M., deBoer, M., Tcheng, J., Vahanian, A., Anderson, K., Weisman, H., Califf, R., & Topol, E. (1998). Complementarity of stenting and abciximab for percutaneous coronary intervention. Journal of the American College of Cardiology, 31, 54–54.

1997

  • Aguirre, F., Simoons, M., Ferguson, J., FitzPatrick, S., Anderson, K., Kern, M., & Tcheng, J. (1997). Impact of contrast media on clinical outcomes following percutaneous coronary interventions with platelet glycoprotein IIb/IIIa inhibition: Meta-analysis of clinical trials with abciximab. Circulation, 96, 898–898.

  • Blankenship, J., Anderson, K., Demko, S., Cabot, C., Kereiakes, D., & Aguirre, F. (1997). Decreased vascular access site bleeding after coronary intervention with abciximab in the EPILOG vs the EPIC trial. Circulation, 96, 896–896.

  • Blankenship, J., Anderson, K., Demko, S., Lincoff, A., Tcheng, J., & Cabot, C. (1997). In-lab angiographic complications during coronary intervention with abciximab vs placebo in the EPILOG trial. Circulation, 96, 905–905.

  • The CAPTURE Investigators. (1997). Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. The Lancet, 349(9063), 1429–1435. https://doi.org/10.1016/S0140-6736(96)10452-9

  • The EPILOG Investigators. (1997). Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine, 336(24), 1689–1697. https://doi.org/10.1056/NEJM199706123362401

  • Gold, H., Kereiakes, D., Dinsmore, R., Martin, L., Lausten, D., Broderick, T., Anderson, K., Garabedian, H., & Leinbach, R. (1997). A randomized, placebo-controlled crossover trial of ReoPro alone or combined with low-dose plasminogen activator for coronary reperfusion in patients with acute myocardial infarction: Preliminary results. Circulation, 96, 2649–2649.

  • Lincoff, A., Tcheng, J., Califf, R., Cabot, C., Miller, D., Booth, J., Montague, E., Anderson, K., & Topol, E. (1997). Abciximab (c7E3 Fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial. Journal of the American College of Cardiology, 29, 7396–7396.

  • Lincoff, A., Tcheng, J., Anderson, K., & Cabot, C. (1997). Durable inhibition of ischemic complications by abciximab during percutaneous coronary revascularization: One-year results of the EPILOG trial. Circulation, 96, 902–902.

  • Lincoff, A., Mark, D., Califf, R., Tcheng, J., Ellis, S., Davidson-Ray, L., Anderson, K., Stoner, G., & Topol, E. (1997). Economic assessment of platelet glycoprotein IIb/IIa receptor blockade during coronary intervention in the EPILOG trial. Journal of the American College of Cardiology, 29, 97484–97484.

  • Lincoff, A. M., Califf, R. M., Anderson, K. M., Weisman, H. F., Aguirre, F. V., Kleiman, N. S., Harrington, R. A., Topol, E. J., & investigators, E. (1997). Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. Journal of the American College of Cardiology, 30(1), 149–156. https://doi.org/10.1016/s0735-1097(97)00110-1

  • Lincoff, A. M., Tcheng, J. E., Califf, R. M., Bass, T., Popma, J. J., Teirstein, P. S., Kleiman, N. S., Hattel, L. J., Anderson, H. V., Ferguson, J. J., et al. (1997). Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. The American Journal of Cardiology, 79(3), 286–291. https://doi.org/10.1016/s0002-9149(96)00749-7

  • Mak, K.-H., Challapalli, R., Eisenberg, M. J., Anderson, K. M., Califf, R. M., Topol, E. J., investigators, E., et al. (1997). Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. The American Journal of Cardiology, 80(8), 985–988. https://doi.org/10.1016/s0002-9149(97)00589-4

  • Simoons, M., Harrington, R., Anderson, K., Deckers, J., & VanPapendrecht, M. (1997). Small, non-Q wave myocardial infarctions during PTCA, are associated with increased 6 months mortality. Circulation, 96, 163–163.

  • Tardiff, B., Anderson, K., Cabot, C., Deckers, J., & Simoons, M. (1997). Reduced need for coronary bypass surgery (CABG) after percutaneous intervention in patients treated with abciximab. Circulation, 96, 931–931.

  • Tcheng, J., Anderson, K., Tardiff, B., Cabot, C., Lincoff, A., Califf, R., & Topol, E. (1997). Reducing the risk of percutaneous intervention after coronary bypass surgery: Beneficial effects of abciximab treatment. Journals of the American College of Cardiology, 29, 7395–7395.

  • Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E., Ellis, S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D. P., Anderson, K. M., et al. (1997). Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA, 278(6), 479–484. https://doi.org/10.1001/jama.1997.03550060055036

1996

  • Aguirre, F. V., Topol, E. J., Anderson, K. M., Kleiman, N. S., Weisman, H. F., FitzPatrick, S. E., & Califf, R. M. (1996). Clinical benefit within patient subgroups receiving c7E3 Fab (abciximab) during percutaneous coronary revascularization: Subgroup analysis from the EPIC trial. The Journal of Invasive Cardiology, 8, 21B–29B.

  • Coller, B. S., Anderson, K. M., & Weisman, H. F. (1996). The anti-GPIIb-IIIa agents: Fundamental and clinical aspects. Pathophysiology of Haemostasis and Thrombosis, 26(Suppl. 4), 285–293. https://doi.org/10.1159/000217309

  • Lefkovits, J., Ivanhoe, R. J., Califf, R. M., Bergelson, B. A., Anderson, K. M., Stoner, G. L., Weisman, H. F., Topol, E. J., Investigators, G. E., et al. (1996). Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. The American Journal of Cardiology, 77(12), 1045–1051. https://doi.org/10.1016/s0002-9149(96)00128-2

  • Mark, D. B., Talley, J. D., Topol, E. J., Bowman, L., Lam, L. C., Anderson, K. M., Jollis, J. G., Cleman, M. W., Lee, K. L., Aversano, T., et al. (1996). Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation, 94(4), 629–635. https://doi.org/10.1161/01.cir.94.4.629

1995

  • Aguirre, F. V., Topol, E. J., Ferguson, J. J., Anderson, K., Blankenship, J. C., Heuser, R. R., Sigmon, K., Taylor, M., Gottlieb, R., Hanovich, G., et al. (1995). Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation, 91(12), 2882–2890. https://doi.org/10.1161/01.cir.91.12.2882

  • Coller, B. S., Anderson, K., & Weisman, H. F. (1995). New antiplatelet agents: Platelet GPIIb/IIIa antagonists. Thrombosis and Haemostasis, 74(07), 302–308. https://doi.org/10.1055/s-0038-1642694

  • Lauer, M. S., Okin, P. M., Larson, M. G., Evans, J. C., Anderson, K. M., & Levy, D. (1995). Impaired heart rate response to graded exercise: Prognostic implications of chronotropic incompetence. Journal of the American College of Cardiology, 25(2), 171A.

  • Lauer, M. S., Okin, P. M., Anderson, K. M., & Levy, D. (1995). Impact of echocardiographic left ventricular mass on mechanistic implications of exercise testing parameters. The American Journal of Cardiology, 76(12), 952–956. https://doi.org/10.1016/s0002-9149(99)80268-9

  • Lefkovits, J., Anderson, K., Weisman, H., Topol, E. J., Investigators, E., et al. (1995). 711-5 mechanism of benefit of platelet IIb/IIIa receptor inhibition in high risk angioplasty in the EPIC trial: A hierarchical endpoint analysis. Journal of the American College of Cardiology, 25(2), 81A.

  • Lefkovits, J., Stoner, G., Anderson, K., Weisman, H., & Topol, E. (1995). Can conjunctive platelet glycoprotein IIb/IIIa receptor blockade improve outcomes of coronary interventions for restenotic lesions. Circulation, 92, 2907–2907.

  • Moliterno, D. J., Califf, R. M., Anderson, K., Weisman, H. F., & Topol, E. J. (1995). 935-34 special considerations for diabetics receiving platelet IIb/IIIa antagonists during coronary interventions: Results from the EPIC trialart. Journal of the American College of Cardiology, 25(2), 155A–156A.

  • Moliterno, D. J., Califf, R. M., Aguirre, F. V., Anderson, K., Sigmon, K. N., Weisman, H. F., Topol, E. J., EPIC Study Investigators, et al. (1995). Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). The American Journal of Cardiology, 75(8), 559–562. https://doi.org/10.1016/s0002-9149(99)80616-x

  • Weisman, H., Schaible, T., Jordan, R., Cabot, C., & Anderson, K. (1995). Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: Experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Biochemical Society Transactions, 23(4), 1051–1057. https://doi.org/10.1042/bst0231051

1994

  • Cole, B. F., Gelber, R. D., & Anderson, K. M. (1994). Parametric approaches to quality-adjusted survival analysis. Biometrics, 621–631. https://doi.org/10.2307/2532777

  • Craen, A. J. de, Weverling, G. J., Anderson, K., & Tijssen, J. G. (1994). Patient randomization and medication distribution independent of the pharmaceutical sponsor. Controlled Clinical Trials, 15(3), 85–86. https://doi.org/10.1016/0197-2456(94)90143-0

  • The EPIC Investigators. (1994). Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine, 330(14), 956–961. https://doi.org/10.1056/NEJM199404073301402

  • Lauer, M. S., Anderson, K. M., Larson, M. G., & Levy, D. (1994). A new method for indexing left ventricular mass for differences in body size. The American Journal of Cardiology, 74(5), 487–491. https://doi.org/10.1016/0002-9149(94)90909-1

  • Lefkovits, J., Anderson, K., Weisman, H., & Topol, E. (1994). Increased risk of non-Q MI following DCA: Evidence for a platelet dependent mechanism from the EPIC trial. Circulation, 90, 214–214.

  • Lefkovits, J., Ivanhoe, R., Anderson, K., Weisman, H., & Topol, E. (1994). Platelet-IIb/IIIa receptor inhibition during PTCA for acute myocardial-infarction—insights from the EPIC trial. Circulation, 90, 564–564.

  • Moliterno, D., Califf, R., Anderson, K., Sigmon, K., Aguirre, F., Weisman, H., & Topol, E. (1994). Activated clotting time is increased during coronary interventions with platelet IIb/IIIa antagonism-results from the EPIC trial. Journal of the American College of Cardiology, A106–A106.

  • Odell, P. M., Anderson, K. M., & Kannel, W. B. (1994). New models for predicting cardiovascular events. Journal of Clinical Epidemiology, 47(6), 583–592. https://doi.org/10.1016/0895-4356(94)90206-2

  • Topol, E., Califf, R., Weisman, H., Anderson, K., Wang, A., & Willerson, J. (1994). 6-month follow-up after acute-phase platelet IIb/IIIa integrin blockade in the EPIC trial-reduction in need for revascularization procedures. Journal of the American College of Cardiology, A60–A60.

  • Topol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley, S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994). Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: Results at six months. The Lancet, 343(8902), 881–886. https://doi.org/10.1016/S0140-6736(94)90007-8

  • Wilson, P. W., Anderson, K. M., Harri, T., Kannel, W. B., & Castelli, W. P. (1994). Determinants of change in total cholesterol and HDL-C with age: The Framingham Study. Journal of Gerontology, 49(6), M252–M257.

1993

  • Anderson, K., Tannenbaum, M., Sanz, M., Wang, A., & Weisman, H. (1993). Clinical events following initially successful PTCA are platelet-mediated—results from the EPIC trial. Circulation, 88, 506–506.

  • Anderson, K. M., Wittes, J., Lee, K. L., Sigmon, K. N., & Weisman, H. F. (1993). Considerations for a group sequential, dose-response trial design. Controlled Clinical Trials, 14(5), 454. https://doi.org/10.1016/0197-2456(93)90197-L

  • Ellis, S. G., Tcheng, J. E., Navetta, F. I., Muller, D., Weisman, H. F., Smith, C., Anderson, K. M., Califf, R. M., & Topol, E. J. (1993). Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Artery Disease, 4(2), 167–175. https://doi.org/10.1097/00019501-199302000-00007

  • Ho, K., Anderson, K. M., Kannel, W. B., Grossman, W., & Levy, D. (1993). Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation, 88(1), 107–115. https://doi.org/10.1161/01.CIR.88.1.107

  • Sutton, J., & Anderson, K. (1993). Body-weight and heparin dosing influence bleeding complications with c7E3 antiplatelet antibody. Circulation, 88, 209–209.

  • Tcheng, J., Topol, E., Kleiman, N., Ellis, S., Navetta, F., Fintel, D., Weisman, H., Anderson, K., Wang, A., Miller, J., et al. (1993). Improvement in clinical outcomes of coronary angioplasty by treatment with the GPIIb/IIIa inhibitor chimeric-7e3-multivariable analysis of the EPIC study. Circulation, 88, 506–506.

1992

  • Anderson, K. M., & Kannel, W. B. (1992). Obesity and disease. In P. Björntorp & B. Brodoff (Eds.), Obesity (pp. 465–473). JB Lippincott Company.

  • Benjamin, E. J., Levy, D., Anderson, K. M., Wolf, P. A., Plehn, J. F., Evans, J. C., Comai, K., Fuller, D. L., & Sutton, M. S. J. (1992). Determinants of doppler indexes of left ventricular diastolic function in normal subjects (the Framingham Heart Study). The American Journal of Cardiology, 70(4), 508–515. https://doi.org/10.1016/0002-9149(92)91199-e

  • Berger, C. J., Murabito, J. M., Evans, J. C., Anderson, K. M., & Levy, D. (1992). Prognosis after first myocardial infarction: Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA, 268(12), 1545–1551. https://doi.org/10.1001/jama.1992.03490120059029

  • Castelli, W. P., Anderson, K., Wilson, P. W., & Levy, D. (1992). Lipids and risk of coronary heart disease The Framingham Study. Annals of Epidemiology, 2(1-2), 23–28. https://doi.org/10.1016/1047-2797(92)90033-m

  • Genest Jr, J., McNamara, J. R., Ordovas, J. M., Jenner, J. L., Silberman, S. R., Anderson, K. M., Wilson, P. W., Salem, D. N., & Schaefer, E. J. (1992). Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. Journal of the American College of Cardiology, 19(4), 792–802. https://doi.org/10.1016/0735-1097(92)90520-w

  • Kannel, W., Anderson, K., & Evans, J. (1992). Relevance of blood lipids in the elderly: The Framingham Study. Cardiovasc Risk Factors, 2, 170–179.

  • Kannel, W. B., Anderson, K., & Wilson, P. W. (1992). White blood cell count and cardiovascular disease: Insights from the Framingham Study. JAMA, 267(9), 1253–1256. https://doi.org/10.1001/jama.1992.03480090101035

  • Kreger, B. E., Anderson, K. M., Schatzkin, A., & Splansky, G. L. (1992). Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study. Cancer, 70(5), 1038–1043. https://doi.org/10.1002/1097-0142(19920901)70:5<1038::aid-cncr2820700505>3.0.co;2-m

  • Lauer, M. S., Anderson, K. M., & Levy, D. (1992). Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: The Framingham Heart Study. Journal of the American College of Cardiology, 19(1), 130–134. https://doi.org/10.1016/0735-1097(92)90063-s

  • Lauer, M. S., Levy, D., Anderson, K. M., & Plehn, J. F. (1992). Is there a relationship between exercise systolic blood pressure response and left ventricular mass? The Framingham Heart Study. Annals of Internal Medicine, 116(3), 203–210. https://doi.org/10.7326/0003-4819-116-3-203

  • Levy, D., Murabito, J. M., Anderson, K. M., Christiansen, J. C., & Castelli, W. P. (1992). Echocardiographic left ventricular hypertrophy: Clinical characteristics. The Framingham Heart Study. Clinical and Experimental Hypertension. Part A: Theory and Practice, 14(1-2), 85–97. https://doi.org/10.3109/10641969209036173

  • O’Leary, D. H., Anderson, K. M., Wolf, P. A., Evans, J. C., & Poehlman, H. W. (1992). Cholesterol and carotid atherosclerosis in older persons: The Framingham Study. Annals of Epidemiology, 2(1-2), 147–153. https://doi.org/10.1016/1047-2797(92)90049-v

  • Odell, P. M., Anderson, K. M., & D’Agostino, R. B. (1992). Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics, 951–959. https://doi.org/10.2307/2532360

  • Singer, D. E., Nathan, D. M., Anderson, K. M., Wilson, P. W., & Evans, J. C. (1992). Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes, 41(2), 202–208. https://doi.org/10.2337/diab.41.2.202

1991

  • Anderson, K. M., Odell, P. M., Wilson, P. W., & Kannel, W. B. (1991). Cardiovascular disease risk profiles. American Heart Journal, 121(1), 293–298. https://doi.org/10.1016/0002-8703(91)90861-b

  • Anderson, K. M., Dumphy, D. C., & Wilson, P. W. F. (1991). Management of data quality in a long-term epidemiologic study: The Framingham Heart Study. In Data quality control theory and pragmatics (pp. 57–68). Marcel Dekker, Inc.

  • Anderson, K. M. (1991). A nonproportional hazards Weibull accelerated failure time regression model. Biometrics, 281–288. https://doi.org/10.2307/2532512

  • Anderson, K. M., Wilson, P., Odell, P. M., & Kannel, W. B. (1991). An updated coronary risk profile: A statement for health professionals. Circulation, 83(1), 356–362. https://doi.org/10.1161/01.CIR.83.1.356

  • Benjamin, E. J., Anderson, K. M., Plehn, J. F., Comai, K., Fuller, D., Evans, J. C., Wolf, P. A., Sutton, M. S. J., & Levy, D. (1991). The impact of age on left ventricular diastolic function in healthy subjects from the Framingham Heart Study. Journal of the American College of Cardiology, 17(2S1), A329–A329.

  • Galderisi, M., Anderson, K. M., Wilson, P. W., & Levy, D. (1991). Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). The American Journal of Cardiology, 68(1), 85–89. https://doi.org/10.1016/0002-9149(91)90716-x

  • Goldberg, R. J., Bengtson, J., Chen, Z., Anderson, K. M., Locati, E., & Levy, D. (1991). Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). The American Journal of Cardiology, 67(1), 55–58. https://doi.org/10.1016/0002-9149(91)90099-7

  • Kreger, B. E., Anderson, K. M., & Levy, D. (1991). QRS interval fails to predict coronary disease incidence: The Framingham Study. Archives of Internal Medicine, 151(7), 1365–1368. https://doi.org/10.1001/archinte.1991.00400070127016

  • Lauer, M. S., Anderson, K. M., Kannel, W. B., & Levy, D. (1991). The impact of obesity on left ventricular mass and geometry: The Framingham Heart Study. JAMA, 266(2), 231–236. https://doi.org/10.1001/jama.1991.03470020057032

  • Lauer, M., Anderson, K., & Levy, D. (1991). The impact of long-term blood-pressure on left-ventricular mass and geometry. Hypertension, 18, 426–426.

  • Lauer, M. S., Anderson, K. M., & Levy, D. (1991). Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: The Framingham Heart Study. Journal of the American College of Cardiology, 18(5), 1287–1294. https://doi.org/10.1016/0735-1097(91)90549-o

  • Okin, P. M., Anderson, K., Levy, D., & Kligfield, P. (1991). Heart rate adjustment of exercise-induced ST segment depression. Improved risk stratification in the Framingham Offspring Study. Circulation, 83(3), 866–874. https://doi.org/10.1161/01.cir.83.3.866

  • Wilson, P. W., Anderson, K. M., & Castelli, W. (1991). The impact of triglycerides on coronary heart disease: The Framingham Study. Athero Rev, 22, 59–63.

  • Wilson, P. W., Anderson, K. M., Castelli, W. P., & Kannel, W. B. (1991). Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: The Framingham Offspring Study. The American Journal of Medicine, 90(1), 11–16. https://doi.org/10.1016/0002-9343(91)90500-w

1990

  • Anderson, K. (1990). Coffee, lipids and cardiovascular disease. The Framingham Offspring Study. Workshop on Coffee and Coronary Heart Disease with Special Emphasis on the Coffee-Blood Lipids Relationship: Proceedings: Three Main Areas, Blood Lipids, Cross-Sectional Studies Experiments, Coffee and Chd, Physiological Mechanisms, 127.

  • Ballard-Barbash, R., Schatzkin, A., Carter, C. L., Kannel, W. B., Kreger, B. E., D’Agostino, R. B., Splansky, G. L., Anderson, K. M., & Helsel, W. E. (1990). Body fat distribution and breast cancer in the Framingham Study. JNCI: Journal of the National Cancer Institute, 82(4), 286–290. https://doi.org/10.1093/jnci/82.4.286

  • Ballard-Barbash, R., Schatzkin, A., Albanes, D., Schiffman, M. H., Kreger, B. E., Kannel, W. B., Anderson, K. M., & Helsel, W. E. (1990). Physical activity and risk of large bowel cancer in the Framingham Study. Cancer Research, 50(12), 3610–3613. https://aacrjournals.org/cancerres/article/50/12/3610/495240/

  • D’Agostino, R. B., Lee, M.-L., Belanger, A. J., Cupples, L. A., Anderson, K., & Kannel, W. B. (1990). Relation of pooled logistic regression to time dependent Cox regression analysis: The Framingham Heart Study. Statistics in Medicine, 9(12), 1501–1515. https://doi.org/10.1002/sim.4780091214

  • Jones, M. G., Anderson, K. M., Wilson, P. W., Kannel, W. B., Wagner, N. B., & Wagner, G. S. (1990). Prognostic use of a QRS scoring system after hospital discharge for initial acute myocardial infarction in the Framingham cohort. The American Journal of Cardiology, 66(5), 546–550. https://doi.org/10.1016/0002-9149(90)90479-k

  • Kannel, W., Anderson, K., & Zhang, T. (1990). White blood-count and cardiovascular disease—insights from the Framingham study. Circulation, 82, 119–119.

  • Kaufman, H. W., McNamara, J. R., Schaefer, E. J., Anderson, K. M., & Wilson, P. W. F. (1990). Portable cholesterol analyzers-reply. JAMA, 264(9), 1102–1103. https://doi.org/10.1001/jama.1990.03450090037015

  • Kaufman, H. W., McNamara, J. R., Anderson, K. M., Wilson, P. W., & Schaefer, E. J. (1990). How reliably can compact chemistry analyzers measure lipids? JAMA, 263(9), 1245–1249. https://doi.org/10.1001/jama.1990.03440090079031

  • Levy, D., Labib, S. B., Anderson, K. M., Christiansen, J. C., Kannel, W. B., & Castelli, W. P. (1990). Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation, 81(3), 815–820. https://doi.org/10.1161/01.cir.81.3.815

  • Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New England Journal of Medicine, 322(22), 1561–1566. https://doi.org/10.1056/NEJM199005313222203

  • Levy, D., Wilson, P. W., Anderson, K. M., & Castelli, W. P. (1990). Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study. American Heart Journal, 119(3), 712–717. https://doi.org/10.1016/s0002-8703(05)80050-x

  • Murabito, J. M., Anderson, K. M., Kannel, W. B., Evans, J. C., & Levy, D. (1990). Risk of coronary heart disease in subjects with chest discomfort: The Framingham Heart Study. The American Journal of Medicine, 89(3), 297–302. https://doi.org/10.1016/0002-9343(90)90341-a

  • Okin, P. M., Anderson, K. M., Lavy, D., & Kligfield, P. (1990). Improved risk in prediction in the Framingham offspring study by heart rate adjustment of ST segment depression. Journal of the American College of Cardiology, 15(2SA), A81–A81.

  • O’Leary, D., Anderson, K., Kase, C., Evans, J., Poehlman, H., & Wolf, P. (1990). Extracranial carotid atherosclerosis in an elderly population—the Framingham study. Circulation, 81, 724–724.

  • Singer, D., Nathan, D., Wilson, P., & Anderson, K. (1990). Hemoglobin A1C as a risk factor for cardiovascular-disease in the Framingham study. Clinical Research, 38, A228–A228.

  • Wilson, P., Kannel, W., Anderson, K., & Castelli, W. (1990). Cholesterol and CHD in the elderly—the Framingham cohort. Circulation, 82, 576–576.

  • Wilson, P., & Anderson, K. (1990). HDL cholesterol and triglycerides as risk factors for CHD. In Atherosclerosis and cardiovascular disease (pp. 609–615). Springer. https://doi.org/10.1007/978-94-009-0731-7_78

1989

  • Ballard-Barbash, R., Schatzkin, A., Carter, C., Kannel, W., Kreger, B., Splansky, G., Anderson, K., & Helsel, W. (1989). Body-fat distribution and breast-cancer in the Framingham Heart Study. American Journal of Epidemiology, 130, 852–853.

  • Castelli, W. P., Wilson, P. W., Levy, D., & Anderson, K. (1989). Cardiovascular risk factors in the elderly. The American Journal of Cardiology, 63(16), 12–19. https://doi.org/10.1016/0002-9149(89)90110-0

  • Hodges, D., Cook, E., Anderson, K., Kannel, W., & Goldman, L. (1989). Alcohol and the risk of congestive heart failure—the Framingham Heart Study. Clinical Research, 37, A313–A313.

  • Kreger, B. E., Anderson, K. M., & Kannel, W. B. (1989). Prevalence of intraventricular block in the general population: The Framingham Study. American Heart Journal, 117(4), 903–910. https://doi.org/10.1016/0002-8703(89)90630-3

  • Preisler, H., Anderson, K., Rai, K., Cuttner, J., Yates, J., DuPre, E., & Holland, J. (1989). The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: A study of 760 patients with a minimal follow-up time of 6 years. British Journal of Haematology, 71(2), 189–194. https://doi.org/10.1111/j.1365-2141.1989.tb04253.x

  • Schatzkin, A., Carter, C. L., Green, S. B., Kreger, B. E., Splansky, G. L., Anderson, K. M., Helsel, W. E., & Kannel, W. B. (1989). Is alcohol consumption related to breast cancer? Results from the Framingham Heart Study. JNCI: Journal of the National Cancer Institute, 81(1), 31–35. https://doi.org/10.1093/jnci/81.1.31

  • Wilson, P. W., Christiansen, J. C., Anderson, K. M., & Kannel, W. B. (1989). Impact of national guidelines for cholesterol risk factor screening: The Framingham Offspring Study. JAMA, 262(1), 41–44. https://doi.org/10.1001/jama.1989.03430010053030

  • Wilson, P., & Anderson, K. (1989). Isolated hypoalphalipoproteinemia and premature heart-disease—the Framingham Offspring Study. Arteriosclerosis, 9, A708–A708.

  • Wilson, P. W. F., Anderson, K. M., & Christiansen, J. C. (1989). Putting cholesterol control on a diet-reply. JAMA, 262(21), 2998–2998. https://doi.org/10.1001/jama.1989.03430210036019

1988

  • Discussion. Risk factors and survival. (1988). Statistics in Medicine, 7(1-2), 297–302. https://doi.org/10.1002/sim.4780070130

  • Cupples, L. A., D’Agostino, R. B., Anderson, K., & Kannel, W. B. (1988). Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Statistics in Medicine, 7(1-2), 205–218. https://doi.org/10.1002/sim.4780070122

  • Hands, M. E., Sia, S. B., Shook, T. L., Anderson, K., Stone, P. H., Levy, D., Castelli, W. P., Rutherford, J. D., Group, F. H. S., et al. (1988). Silent myocardial ischemia in asymptomatic survivors of unrecognized myocardial infarction and matched controls. American Heart Journal, 116(6), 1488–1492. https://doi.org/10.1016/0002-8703(88)90733-8

  • Levy, D., Anderson, K. M., Christiansen, J. C., Campanile, G., & Stokes III, J. (1988). Antihypertensive drug therapy and arrhythmia risk. The American Journal of Cardiology, 62(1), 147–149. https://doi.org/10.1016/0002-9149(88)91383-5

  • Levy, D., Anderson, K. M., Savage, D. D., Kannel, W. B., Christiansen, J. C., & Castelli, W. P. (1988). Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors: The Framingham Heart Study. Annals of Internal Medicine, 108(1), 7–13. https://doi.org/10.7326/0003-4819-108-1-7

  • O’Leary, D., Anderson, K., Kase, C., Wolf, P., & Kannel, W. (1988). Extracranial carotid atherosclerosis in a general population—the Framingham Study. Stroke, 19, 143–143.

  • Singer, D., Nathan, D., Wilson, P., & Anderson, K. (1988). Glycated hemoglobin is associated with cardiovascular-disease in females of the Framingham cohort, even among non-diabetics. Clinical Research, 36, A350–A350.

1987

  • Anderson, K. M., Castelli, W. P., & Levy, D. (1987). Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA, 257(16), 2176–2180. https://doi.org/10.1001/jama.1987.03390160062027

  • Anderson, K. M. (1987). Cholesterol and mortality-reply. JAMA, 258(12), 1609–1609. https://doi.org/10.1001/jama.1987.03400120058023

  • Anderson, K. M., Wilson, P. W., Garrison, R. J., & Castelli, W. P. (1987). Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample The Framingham Offspring Study. Atherosclerosis, 68(1-2), 59–66. https://doi.org/10.1016/0021-9150(87)90094-3

  • Kannel, W. B., Anderson, K., McGee, D. L., Degatano, L. S., & Stampfer, M. J. (1987). Nonspecific electrocardiographic abnormality as a predictor of coronary heart disease: The Framingham Study. American Heart Journal, 113(2), 370–376. https://doi.org/10.1016/0002-8703(87)90280-8

  • Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel, W. B., & Castelli, W. P. (1987). Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study. The American Journal of Cardiology, 59(9), 956–960. https://doi.org/10.1016/0002-9149(87)91133-7

  • Levy, D., Anderson, K. M., Plehn, J., Savage, D. D., Christiansen, J. C., & Castelli, W. P. (1987). Echocardiographically determined left ventricular structural and functional correlates of complex or frequent ventricular arrhythmias on one-hour ambulatory electrocardiographic monitoring. The American Journal of Cardiology, 59(8), 836–840. https://doi.org/10.1016/0002-9149(87)91102-7

  • Levy, D., Anderson, K., Savage, D., Kannel, W., & Castelli, W. (1987). Influence of 30 year mean blood-pressure levels on left-ventricular mass—the Framingham Heart Study. Journal of the American College of Cardiology, 9, A115–A115.

  • Levy, D., Anderson, K. M., Savage, D. D., Balkus, S. A., Kannel, W. B., & Castelli, W. P. (1987). Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. The American Journal of Cardiology, 60(7), 560–565. https://doi.org/10.1016/0002-9149(87)90305-5

  • O’Connor, G., Anderson, K., Kannel, W., Brand, F., Christiansen, J., Weiss, S., & Speizer, F. (1987). Prevalence and prognosis of dyspnea in the Framingham Study. Chest, 92(Suppl 2), 90S.

  • Plehn, J., Levy, D., Anderson, K., Savage, D., & Stokes, J. (1987). Failure of exercise blood-pressure parameters to predict left-ventricular mass—the Framingham Heart Study. Journal of the American College of Cardiology, 9, A51–A51.

1986

  • Anderson, K., Castelli, W., & Stokes, J. (1986). Repeated measures of body-mass index and mortality—the Framingham study. American Journal of Epidemiology, 124, 514–514.

  • Castelli, W. P., & Anderson, K. (1986). A population at risk: Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. The American Journal of Medicine, 80(2), 23–32. https://doi.org/10.1016/0002-9343(86)90157-9

  • Levy, D., Anderson, K., Christiansen, J., & Stokes, J. (1986). Prevalence of ventricular arrhythmias in hypertensives treated with β-blockers or diuretics—the Framingham Heart Study. Circulation, 74, 489–489.

  • Olson, W., Bennett, T., Huberty, K., & Anderson, K. (1986). Automatic detection of ventricular-fibrillation with chronically implanted pressure sensors. Journal of the American College of Cardiology, 7, A182–A182.

  • Sharma, A., Sutton, R., Bennett, T., Klein, G., Anderson, K., & Beck, R. (1986). Physiological pacing based on beat-to-beat measurement of right ventricular dP/dtmax—initial feasibility studies in man. Journal of the American College of Cardiology, 7, A3–A3.

  • Sobol, R. E., Mick, R., Lebien, T. W., Ozer, H., Minowada, J., Anderson, K., Ellison, R. R., Cuttner, J., Morrison, A., Richards II, F., et al. (1986). The reproducibility of acute lymphoblastic leukemia phenotype determinations: Evaluation of monoclonal antibody and conventional hematopoietic markers. Leukemia Research, 10(5), 481–485. https://doi.org/10.1016/0145-2126(86)90083-4

  • Wilson, P. W., Anderson, K. M., & Kannel, W. B. (1986). Epidemiology of diabetes mellitus in the elderly: The Framingham Study. The American Journal of Medicine, 80(5), 3–9. https://doi.org/10.1016/0002-9343(86)90532-2

1985

  • Bennett, T., Baudino, M., Bornzin, G., Anderson, K., & Olson, W. (1985). Rate-responsive pacing using dynamic right ventricular pressure in heart-blocked dogs. Journal of the American College of Cardiology, 5, 393–393.

  • Goetzler, R., Stokes III, J., & Anderson, K. (1985). Prognosis of subjects in the Framingham Study with rheumatic heart disease. Journal of the American Geriatrics Society, 33(10), 693–697. https://doi.org/10.1111/j.1532-5415.1985.tb01778.x

  • Kreger, B., Provencher, L., Anderson, K., & Kannel, W. (1985). Prevalence of intraventricular block in the general population—the Framingham study. Journal of the American College of Cardiology, 5, 443–443.

  • Levy, D., Savage, D., Garrison, R., Balkus, S., Anderson, K., Kannel, W., & Castelli, W. (1985). The association of left-ventricular hypertrophy with ventricular arrhythmias—the Framingham Heart Study. Circulation, 72, 46–46.

  • Sobol, R., Royston, I., LeBien, T., Minowada, J., Anderson, K., Davey, F., Cuttner, J., Schiffer, C., Ellison, R., & Bloomfield, C. (1985). Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies. Blood, 65(3), 730–735. https://doi.org/10.1182/blood.V65.3.730.730

  • Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., & Lee, J. E. (1985). Early precursors of site-specific cancers in college men and women. JNCI: Journal of the National Cancer Institute, 74(1), 43–51. https://doi.org/10.1093/jnci/74.1.43

  • Wilson, P., Kannel, W., & Anderson, K. (1985). Lipids, glucose intolerance and vascular disease: The Framingham Study. Monographs on Atherosclerosis, 13, 1–11.

1984

1983

  • Anderson, K. (1983). Convergence of the moment generating function of standardized quantiles. Communications in Statistics-Theory and Methods, 12(21), 2445–2454. https://doi.org/10.1080/03610928308828611

  • Hauck, W. W., Whittemore, A. S., McLarty, J. W., Fortson, N., & Anderson, K. (1983). Regression analysis of cytopathological data-reply. Biometrics, 39(4), 1114–1114. http://www.jstor.org/stable/2531348

  • Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., & Halpern, J. (1983). Early precursors of pancreatic cancer in college men. Journal of Chronic Diseases, 36(3), 251–256. https://doi.org/10.1016/0021-9681(83)90059-0

1982

1980